Menu
Recruiting NCT06071403

The Effects of Time Points to Cease Parenteral Nutrition and IGF-1 on Very Low Birth Weight Infants

Observational Growth Retardation

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: (enteral feeding volume/ total fluid volume)*100%.
Who it may be relevant to
Registry conditions: Growth Retardation. Basic parameters: No limits · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

The Effects of Time Points to Cease Parenteral Nutrition and IGF-1 on Very Low Birth Weight Infants--A Multicenter Prospective Cohort Study

Overview

This study aims to estimate short-term and long-term effects of time points to cease parenteral nutrition on very preterm infants, such as growth; to estimate the role of insulin-like growth factor 1 in the growth.

Detailed description

At present, it is unclear when to cease parenteral nutrition, the effects of cessation times on preterm infants' growth, and whether insulin-like growth factor 1 (IGF-1) has a mediation effect in the procedure that nutrients regulate the growth in preterm infants.

Therefore, a prospective cohort study was designed with the aims:

1. to estimate the association between the time to cease parenteral nutrition and the growth in very low birth weight; 2. to investigate the relationship between nutrient volume in parenteral nutrition and growth in very low birth weight; 3. to analyze the IGF-1 mediation effect between nutrient volume and growth regulations.

Interventions

  • Other (enteral feeding volume/ total fluid volume)*100%
    (enteral feeding volume/ total fluid volume)\*100%. Total fluid volume is defined as enteral feeding volume + parenteral fluid volume + other fluid volume

Primary outcome measures

  • short-term weight and long-term weight [Time frame: at 36 weeks' corrected age (CA), CA 3 months, CA 6 months, CA 12 months, CA 18 months, CA 24 months, 36 months' age, 48 months' age and 60 months' age]
  • short-term head circumference and long-term head circumference [Time frame: at 36 weeks' corrected age (CA), CA 3 months, CA 6 months, CA 12 months, CA 18 months, CA 24 months, 36 months' age, 48 months' age and 60 months' age]
  • short-term length and long-term length [Time frame: at 36 weeks' corrected age (CA), CA 3 months, CA 6 months, CA 12 months, CA 18 months, CA 24 months, 36 months' age, 48 months' age and 60 months' age]

Eligibility criteria

Inclusion criteria

  • Infants with a birth weight less than 1500 grams
  • Infants admitted within 72 hours after birth
  • Infants born from July 1, 2023, to June 30, 2024
  • Written informed consent from parents or guardians

Exclusion criteria

  • Infants with congenital abnormality
  • Infants surviving <7 days after birth

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Cohort

Study locations

China · 1 center
  • Wei Guo — Xingtai

Identifiers

NCT: NCT06071403 · IRB00001052-23093

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗